MYLAN-AZITHROMYCIN TABLET

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE)

থেকে পাওয়া:

MYLAN PHARMACEUTICALS ULC

এটিসি কোড:

J01FA10

INN (আন্তর্জাতিক নাম):

AZITHROMYCIN

ডোজ:

250MG

ফার্মাসিউটিকাল ফর্ম:

TABLET

রচনা:

AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE) 250MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

6/30

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

OTHER MACROLIDES

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0126072001; AHFS:

অনুমোদন অবস্থা:

CANCELLED POST MARKET

অনুমোদন তারিখ:

2018-03-09

পণ্য বৈশিষ্ট্য

PRODUCT MONOGRAPH
PR
MYLAN-AZITHROMYCIN
Azithromycin Tablets
250 mg
USP
ANTIBACTERIAL AGENT
MYLAN PHARMACEUTICALS ULC
85 Advance Road
Etobicoke, Ontario
M8Z 2S6
Date of Revision:
February 8, 2018
Control number: 213343
_ _
_MYLAN-AZITHROMYCIN Product Monograph _
_Page 2 of 62_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................5
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................15
DOSAGE AND ADMINISTRATION
..............................................................................21
OVERDOSAGE
................................................................................................................22
ACTION AND CLINICAL PHARMACOLOGY
............................................................22
STORAGE AND STABILITY
..........................................................................................25
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II: SCIENTIFIC INFORMATION
...............................................................................26
PHARMACEUTICAL INFORMATION
..........................................................................26
CLINICAL TRIALS
..........................................................................................................27
DETAILED PHARMACOLOGY
..............................................................................